What is Artemis Therapeutics Inc. (ATMS) stock price today?

Artemis Therapeutics Inc. (ATMS) is currently trading at $0.50, down 73.65% today.

What is ATMS P/E ratio?

Artemis Therapeutics Inc.'s P/E ratio is -49.80. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ATMS return on equity (ROE)?

Artemis Therapeutics Inc.'s return on equity (ROE) is 177.53%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Artemis Therapeutics Inc.'s market cap?

Artemis Therapeutics Inc. has a market capitalization of $55.79M.

OTC · Shell Companies

Artemis Therapeutics Inc. (ATMS) Stock

$0.50 -73.65% OTC: ATMS Financial Services

Artemis Therapeutics Inc. currently lacks substantial business operations.

Valuation

Metric	Value
Price	$0.50
Market Cap	$55.79M
P/E Ratio	-49.80
P/B Ratio	-27694.96
P/S Ratio	179.40
EPS (TTM)	$-0.01
52-Week High	$4.50
52-Week Low	$0.11
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	177.53%
ROA	-509.81%
ROCE	183.90%
Gross Margin	82.64%
Operating Margin	-436.98%
Net Margin	-434.41%
Debt/Equity	-0.35
Current Ratio	0.14

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-1.0M	$0	$0	$0	$-1.0M
Net Profit	$1.0M	$0	$0	$0	$-1.0M
EPS	$-0.10	$-0.02	$-0.02	$-0.01	$-0.01
Op Margin	-298.1%	—	—	—	-437.0%

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$0	$0	$0	$0	$0
Total Liabilities	$0	$0	$0	$1.0M	$1.0M
Cash	$0	$0	$0	$0	$0
Borrowings	$0	$0	$0	$0	$0

Latest News

A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position Motley Fool · Jul 23, 2026 Genomma Lab Internacional Announces Results for the Second Quarter 2026 PR Newswire · Jul 23, 2026 Cathay General Bancorp Q2 Earnings Call Highlights MarketBeat · Jul 23, 2026 Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment MarketBeat · Jul 23, 2026 When the Market Drops, the IRS Quietly Discounts Your Roth Conversion. Here’s the Math at $500,000 24/7 Wall St. · Jul 23, 2026

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-1.0M	$0	$0	$0	$0
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$-1.0M	$0	$0	$0	$0
Free Cash Flow	$-1.0M	$0	$0	$0	$0

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.15
EV / EBITDA	-41.77
FCF Yield	-0.75%
Quick Ratio	0.10
Interest Coverage	0.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$313.33	+0.29%	37.72	$4.60T	0.34%
MSFTMicrosoft Corporation	$499.99	+0.03%	22.95	$3.71T	0.94%
GOOGLAlphabet Inc.	$354.30	-0.96%	27.68	$4.29T	0.23%
AMZNAmazon.com, Inc.	$274.48	+0.82%	28.76	$2.95T	0.00%
METAMeta Platforms, Inc.	$592.10	+0.37%	21.47	$1.51T	0.35%

About Artemis Therapeutics Inc.

Artemis Therapeutics Inc. currently lacks substantial business operations. Situated in New York, New York, this company previously concentrated on developing pharmaceutical agents to prevent and treat severe and life-threatening infectious diseases. It is a subsidiary of Tonak Ltd.

Artemis Therapeutics Inc. is headquartered in US.

Artemis Therapeutics Inc. (ATMS) stock trades at $0.50 with a market capitalization of $55.79M. The stock is valued at a price-to-earnings (P/E) ratio of -49.80, price-to-book of -27694.96, price-to-sales of 179.40. Over the past 52 weeks the stock has ranged between $0.11 and $4.50, and currently trades 88.9% below its 52-week high.

On profitability, Artemis Therapeutics Inc. generates a return on equity (ROE) of 177.53% — well above the market average, a sign of a high-quality business, return on capital employed of 183.90%, an operating margin of -436.98%, a net profit margin of -434.41%.

Official website: www.artemis-therapeutics.com